While inhibitors of both canonical and noncanonical NF‐κB pathways can inhibit the proliferation of PEL cell lines, these inhibitors usually have systematic and on‐target toxicities, which limit their clinical usage [54, 55]. The gene discussed is NFKB1; the disease is primary effusion lymphoma.